Hepatitis  >>  emricasan (IDN 6556)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
emricasan (IDN 6556) / Amerimmune
NCT00088140: A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Completed
2
204
US
IDN-6556, Placebo
Conatus Pharmaceuticals Inc., Idun Pharmaceuticals
Hepatitis C, Chronic
10/05
10/05
NCT00080236: Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Completed
2
99
US, Europe
IDN-6556, Placebo
Conatus Pharmaceuticals Inc., Idun Pharmaceuticals
Liver Transplantation, Hepatitis, Cholestasis, Carcinoma, Hepatocellular
01/06
01/06
NCT01937130 / 2012-004245-33: Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Terminated
2
23
US, Europe
IDN-6556, emricasan, PF-03491390, Placebo
Conatus Pharmaceuticals Inc.
Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
01/15
02/15
NCT01912404: Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy

Terminated
2
5
US
IDN-6556, emricasan, PF-03491390, Placebo
Conatus Pharmaceuticals Inc., National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcoholic Hepatitis
08/15
08/15

Download Options